Marker Therapeutics (NASDAQ:MRKR) Shares Down 3.3% – Here’s Why

Marker Therapeutics, Inc. (NASDAQ:MRKR) shares fell 3.3% during trading on Monday . The company traded as low as $1.45 and last traded at $1.46. 34,640 shares were traded during trading, a decline of 47% from the average daily volume of 65,132 shares. The stock had previously closed at $1.51.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MRKR. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, June 24th. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Wednesday, May 20th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Marker Therapeutics presently has an average rating of “Hold” and a consensus price target of $10.00.

Marker Therapeutics Stock Down 3.3%

The stock has a market cap of $24.34 million, a price-to-earnings ratio of -2.39 and a beta of 1.45. The company’s 50-day moving average is $1.44 and its 200-day moving average is $1.52.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%.The company had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.78 million. On average, research analysts forecast that Marker Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Trading of Marker Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in Marker Therapeutics during the third quarter worth $25,000. Two Sigma Investments LP acquired a new stake in shares of Marker Therapeutics in the 3rd quarter valued at $33,000. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics in the 2nd quarter valued at $33,000. Boyer Financial Services Inc. acquired a new stake in shares of Marker Therapeutics in the 4th quarter valued at $57,000. Finally, XTX Topco Ltd grew its holdings in shares of Marker Therapeutics by 166.6% in the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares during the last quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.